Date published: 2025-12-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

MAGE-B16 Inhibitors

MAGE-B16 inhibitors pertain to a distinctive and intriguing chemical class that has garnered substantial attention due to its pivotal involvement in modulating specific and crucial biological pathways. These inhibitors, characterized by their ability to interact with a specific target protein known as MAGE-B16, possess intricate molecular architectures marked by a diverse array of functional groups and structural motifs. This structural diversity plays a critical role in their ability to effectively engage with the active site of MAGE-B16, thereby eliciting a potent inhibitory response. Extensive research efforts have been directed towards unraveling the intricacies of the molecular interactions that underlie the binding of MAGE-B16 inhibitors to their target protein. These investigations have provided insights into the three-dimensional structure of MAGE-B16 and the exact nature of the interactions that occur at the binding interface. The design and synthesis of these inhibitors necessitate a meticulous understanding of the intricate interplay between the inhibitor's structural features and the specific molecular recognition requirements of the target protein. The scientific community has successfully synthesized a diverse array of MAGE-B16 inhibitors with varying degrees of affinity and selectivity. This achievement not only showcases the strides made in the field of molecular design but also contributes significantly to our comprehension of the functional relevance of MAGE-B16 in biological processes. The wealth of synthesized inhibitors opens up promising avenues for further exploration, allowing researchers to delve into the intricacies of MAGE-B16's involvement in various cellular pathways and facilitating a deeper understanding of its potential implications across different scientific domains.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Ibrutinib

936563-96-1sc-483194
10 mg
$153.00
5
(0)

Ibrutinib was one of the first BTK inhibitors. It covalently binds to BTK, preventing its activation and downstream signaling, thereby inhibiting B-cell proliferation and survival.

Acalabrutinib

1420477-60-6sc-507392
250 mg
$255.00
(0)

Acalabrutinib is a BTK inhibitor. It is designed to have higher selectivity for BTK and to bind reversibly, potentially reducing off-target effects.

Zanubrutinib

1691249-45-2sc-507434
5 mg
$360.00
(0)

Zanubrutinib is a BTK inhibitor. It is designed to have a higher degree of selectivity for BTK.